Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany

BACKGROUND: In Germany, several triplet therapies for treating relapsed or refractory multiple myeloma (rrMM) patients have recently been approved. While most of them are administered intravenously, ixazomib-based combination is the only orally bioavailable regimen. OBJECTIVE: To conduct a 1-year an...

Descripción completa

Detalles Bibliográficos
Autores principales: Basic, Edin, Kappel, Mathias, Misra, Arpit, Sellner, Leopold, Ratsch, Boris A., Ostwald, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581591/
https://www.ncbi.nlm.nih.gov/pubmed/32654072
http://dx.doi.org/10.1007/s10198-020-01219-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581591/
https://www.ncbi.nlm.nih.gov/pubmed/32654072
http://dx.doi.org/10.1007/s10198-020-01219-3

Ejemplares similares